Payload ID	PAY0IJDGO
Name	Ed9
Target	DNA topoisomerase 1 (TOP1)					Target Info
Structure
				2D MOL
Isosmiles	O=C(N[C@H]1CCC2=C3C(N=C4C(CN5C(C6=C([C@@](CC)(C(OC6)=O)O)C=C54)=O)=C31)=CC(F)=C2C)C7(CCC7)O

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	1.17	nM	NCI-N87 cells	Gastric tubular adenocarcinoma	CVCL_1603	[1]
Half Maximal Inhibitory Concentration (IC50)	1.17	nM	NCI-N87 cells	Gastric tubular adenocarcinoma	CVCL_1603	[1]
Half Maximal Inhibitory Concentration (IC50)	1.69	nM	MDA-MB-361 cells	Breast adenocarcinoma	CVCL_0620	[1]
Half Maximal Inhibitory Concentration (IC50)	1.69	nM	MDA-MB-361 cells	Breast adenocarcinoma	CVCL_0620	[1]
Half Maximal Inhibitory Concentration (IC50)	120.3	nM	MDA-MB-453 cells	Breast adenocarcinoma	CVCL_0418	[1]
Half Maximal Inhibitory Concentration (IC50)	120.3	nM	MDA-MB-453 cells	Breast adenocarcinoma	CVCL_0418	[1]
Half Maximal Inhibitory Concentration (IC50)	13.14	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[1]
Half Maximal Inhibitory Concentration (IC50)	13.14	nM	SK-BR-3 cells	Breast adenocarcinoma	CVCL_0033	[1]
Half Maximal Inhibitory Concentration (IC50)	193.3	nM	JIMT-1 cells	Breast ductal carcinoma	CVCL_2077	[1]
Half Maximal Inhibitory Concentration (IC50)	193.3	nM	JIMT-1 cells	Breast ductal carcinoma	CVCL_2077	[1]
Half Maximal Inhibitory Concentration (IC50)	2.69	nM	MDA-MB-231 cells	Breast adenocarcinoma	CVCL_0062	[1]
Half Maximal Inhibitory Concentration (IC50)	2.69	nM	MDA-MB-231 cells	Breast adenocarcinoma	CVCL_0062	[1]
Half Maximal Inhibitory Concentration (IC50)	2.69	nM	MDA-MB-231 cells	Breast carcinoma	CVCL_0062	[1]

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.30%
In Vivo Model	NCI-N87/MDA-MB-231 co-incubation model 2 mpk
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100%
In Vivo Model	NCI-N87 CDX model 3 mpk
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100%
In Vivo Model	NCI-N87 CDX model 1 mpk

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.071 nM
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.091 nM
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.674 nM
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.091 nM
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.331 nM
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Ref 1	Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors